Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 1.00 |
| ▸ | CDK3 | Q00526 | 19/20 | 1.00 |
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CDK1 | P06493 | 13/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 13/20 | 1.00 |
| ▸ | AURKA | O14965 | 12/20 | 1.00 |
| ▸ | GRK2 | P25098 | 11/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12901291 | 0.91 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL1273924 | 0.91 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12901192 | 0.91 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL1274544 | 0.89 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12901160 | 0.88 | CCNE1 (0.80) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12935053 | 0.88 | CCNE1 (0.79) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12901196 | 0.87 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL1274189 | 0.87 | CCNE1 (1.00) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12901163 | 0.87 | CCNE1 (0.85) | CCNE1CDK3CDK2CDK1CCNB1 | |
| SCHEMBL12901181 | 0.86 | CCNE1 (0.86) | CCNE1CDK3CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879887-B2 | such as 2-(4-chloro-3-hydroxyphenylamino)-N-(6H-pyrazolo[4',3':3,4]benzo[1,2-d]thiazol-2-yl)-acetamide, having antitumor activity, particularly dual inhibitory activity on Aurora kinase and cyclin-dependent kinase (CDK), and are useful for cell proliferative diseases such as cancer | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-2045253-A1 | a-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT | Nissan Chemical Industries, Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275623-A1 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CCNA1, AURKA, CDK1 | CCNE1 12/4885CDK3 23/4885CDK2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.